Central retinal vein occlusion

Nov 06, 2019

Bioeq Announces Coherus as Marketing and Distribution Partner for Its Biosimilar to Lucentis® (ranibizumab) in the U.S.

Oct 25, 2018

EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial

Sep 13, 2018

FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy

Aug 17, 2018

FDA Approves EYLEA® (aflibercept) Injection sBLA in Wet Age-related Macular Degeneration

Feb 06, 2018

Global Retinal Disorders Landscape Report 2017

Jan 03, 2018

Momenta and Mylan Announce Development Strategy for M710, a Proposed Biosimilar to EYLEA® (aflibercept)

Dec 11, 2017

Regeneron Announces FDA Acceptance of sBLA Filing for 12-Week Dosing of EYLEA® (aflibercept) Injection for Patients with Wet AMD

Oct 30, 2017

Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)